FI94489C - Menetelmä ristisuojaavien ihmisen monoklonaalisten vasta-aineiden valmistamiseksi ja vasta-ainetta tuottava solulinja - Google Patents

Menetelmä ristisuojaavien ihmisen monoklonaalisten vasta-aineiden valmistamiseksi ja vasta-ainetta tuottava solulinja Download PDF

Info

Publication number
FI94489C
FI94489C FI870502A FI870502A FI94489C FI 94489 C FI94489 C FI 94489C FI 870502 A FI870502 A FI 870502A FI 870502 A FI870502 A FI 870502A FI 94489 C FI94489 C FI 94489C
Authority
FI
Finland
Prior art keywords
antibody
antibodies
coli
bacterial
serotypes
Prior art date
Application number
FI870502A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI870502L (fi
FI94489B (fi
FI870502A0 (fi
Inventor
Howard V Raff
Original Assignee
Squibb Bristol Myers Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Squibb Bristol Myers Co filed Critical Squibb Bristol Myers Co
Publication of FI870502A0 publication Critical patent/FI870502A0/fi
Publication of FI870502L publication Critical patent/FI870502L/fi
Publication of FI94489B publication Critical patent/FI94489B/fi
Application granted granted Critical
Publication of FI94489C publication Critical patent/FI94489C/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
FI870502A 1986-02-07 1987-02-06 Menetelmä ristisuojaavien ihmisen monoklonaalisten vasta-aineiden valmistamiseksi ja vasta-ainetta tuottava solulinja FI94489C (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US82800586A 1986-02-07 1986-02-07
US82800586 1986-02-07
US94449586A 1986-12-19 1986-12-19
US94449586 1986-12-19

Publications (4)

Publication Number Publication Date
FI870502A0 FI870502A0 (fi) 1987-02-06
FI870502L FI870502L (fi) 1987-08-08
FI94489B FI94489B (fi) 1995-06-15
FI94489C true FI94489C (fi) 1995-09-25

Family

ID=27125154

Family Applications (1)

Application Number Title Priority Date Filing Date
FI870502A FI94489C (fi) 1986-02-07 1987-02-06 Menetelmä ristisuojaavien ihmisen monoklonaalisten vasta-aineiden valmistamiseksi ja vasta-ainetta tuottava solulinja

Country Status (28)

Country Link
US (2) US5717071A (Direct)
JP (1) JP2645343B2 (Direct)
KR (1) KR870007697A (Direct)
CN (1) CN87102167A (Direct)
AT (1) AT398781B (Direct)
BE (1) BE1000967A5 (Direct)
CA (1) CA1339013C (Direct)
CH (1) CH672072A5 (Direct)
DE (1) DE3703711A1 (Direct)
DK (1) DK63187A (Direct)
ES (1) ES2009140A6 (Direct)
FI (1) FI94489C (Direct)
FR (1) FR2595946B1 (Direct)
GB (1) GB2186592B (Direct)
GR (1) GR870194B (Direct)
HK (1) HK21795A (Direct)
HU (1) HU203583B (Direct)
IE (1) IE59627B1 (Direct)
IL (1) IL81370A (Direct)
IT (1) IT1207589B (Direct)
LU (1) LU86761A1 (Direct)
MX (1) MX9203629A (Direct)
NL (1) NL8700286A (Direct)
NO (1) NO176924C (Direct)
NZ (2) NZ233920A (Direct)
OA (1) OA08477A (Direct)
PT (1) PT84258B (Direct)
SE (1) SE468747B (Direct)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0256713A3 (en) * 1986-08-06 1989-02-15 Merck & Co. Inc. Therapeutic human antipseudomonas aeruginosa antibodies
CA1341375C (en) * 1988-10-12 2002-07-09 Baxter International Inc. Compositions and methods for the treatment and prevention of gram-negative bacterial infections
DE3925161A1 (de) * 1989-03-15 1990-09-27 Boehringer Mannheim Gmbh Monoklonale, gegen eca gerichtete antikoerper und ihre verwendung
WO1990013660A2 (en) * 1989-05-09 1990-11-15 Cetus Corporation Human monoclonal antibodies to sero-specific determinants of gram-negative bacteria
US6315999B1 (en) 1989-08-10 2001-11-13 Solvay, S.A. Pharmaceutical product for the treatment of sepsis
GB8918232D0 (en) * 1989-08-10 1989-09-20 Opal Stephen M Pharmaceutical product for the treatment of septic shock
US20080139789A1 (en) * 1990-10-22 2008-06-12 Henry M. Jackson Foundation For The Advancement Of Military Medicine Isolated Broadly Reactive Opsonic Immunoglobulin for Treating a Pathogenic Coagulase-Negative Staphylococcus Infection
AU3805893A (en) * 1992-03-19 1993-10-21 U.S. Government, As Represented By The Secretary Of The Army Broadly reactive opsonic antibodies that react with common staphylococcal antigens
CA2153661A1 (en) * 1993-01-12 1994-07-21 Anthony George Gristina Methods and compositions for the direct concentrated delivery of passive immunity
US5510264A (en) * 1993-09-28 1996-04-23 Insight Biotech Inc. Antibodies which bind meningitis related homologous antigenic sequences
DE69942607D1 (de) * 1998-04-14 2010-09-02 Chugai Pharmaceutical Co Ltd Neues cytokinartiges protein
ES2397488T3 (es) * 2007-07-23 2013-03-07 Sanofi Pasteur Limited Polipéptidos inmunógenos y anticuerpos monoclonales
US8444983B2 (en) * 2009-03-23 2013-05-21 Quark Pharmaceuticals, Inc. Composition of anti-ENDO180 antibodies and methods of use for the treatment of cancer and fibrotic diseases
MX2013006255A (es) 2010-12-03 2015-08-05 Sanofi Pasteur Ltd Composicion para inmunizacion contra streptococcus pneumoniae.
EP3374391B1 (en) 2015-11-10 2024-04-17 Visterra, Inc. Antibody molecule-drug conjugates that specifically binds to lipopolysaccharide and uses thereof
KR102697723B1 (ko) 2017-01-18 2024-08-21 비스테라, 인크. 항체 분자-약물 접합체 및 이의 용도
CA3178465A1 (en) 2020-04-03 2021-10-07 Visterra, Inc. Antibody molecule-drug conjugates and uses thereof
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
US12537071B1 (en) 2020-07-22 2026-01-27 David Gordon Bermudes Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4464465A (en) * 1982-04-05 1984-08-07 Genetic Systems Corporation Cell-driven viral transfer in eukaryotes
CA1262238C (en) * 1982-09-30 1989-10-10 HUMAN MONOCLONAL ANTIBODIES AGAINST BACTERIAL TOXINS
US4587121A (en) * 1983-06-14 1986-05-06 Miles Laboratories, Inc. High titer Pseudomonas immune serum globulin
US5179018A (en) * 1983-10-14 1993-01-12 Centocor, Inc. Mamalian monoclonal antibodies against endotoxin of gram-negative bacteria
US4834975A (en) * 1984-05-25 1989-05-30 Genetics Corporation Human monoclonal antibodies to serotypic lipopolysaccharide determinants on gram-negative bacteria and their production
DE3426903A1 (de) * 1984-07-20 1986-01-23 Biotest Pharma GmbH, 6000 Frankfurt Eine immunglobulinpraeparation in kombination mit einer anderen pharmakologisch wirksamen praeparation zur verwendung bei der behandlung von krankheiten
US4675287A (en) * 1984-07-26 1987-06-23 Scripps Clinic And Research Foundation Monoclonal antibody directed to human ganglioside GD2
US4677070A (en) * 1985-04-26 1987-06-30 Cetus Corporation Pseudomonas aeruginosa exotoxin A antibodies, their preparation and use
US4772464A (en) * 1985-08-01 1988-09-20 Miles Laboratories, Inc. Protective antibodies to serotypic determinants of flagellar antigens
US4918163A (en) * 1985-09-27 1990-04-17 Pfizer Inc. Monoclonal antibodies specific for lipid-A determinants of gram negative bacteria
US4777136A (en) * 1985-09-27 1988-10-11 The Regents Of The University Of California Monoclonal antibody reactive with Pseudomonas Aeruginosa
NZ218499A (en) * 1985-12-10 1990-04-26 Genetic Systems Corp Monoclonal antibodies against pseudomonas aeruginosa, pharmaceutical compositions and detection methods
US4970070A (en) * 1986-02-07 1990-11-13 Genetic Systems Corporation Protective monoclonal antibody compositions for infections due to group B streptococcus

Also Published As

Publication number Publication date
IT8719292A0 (it) 1987-02-06
HUT46062A (en) 1988-09-28
FI870502L (fi) 1987-08-08
OA08477A (fr) 1988-07-29
JP2645343B2 (ja) 1997-08-25
SE468747B (sv) 1993-03-15
NO870476L (no) 1987-08-10
GB2186592A (en) 1987-08-19
CA1339013C (en) 1997-03-25
MX9203629A (es) 1992-07-01
SE8700467D0 (sv) 1987-02-06
DK63187D0 (da) 1987-02-06
ES2009140A6 (es) 1989-09-01
IE870320L (en) 1987-08-07
FI94489B (fi) 1995-06-15
IL81370A (en) 1991-06-30
JPS62270535A (ja) 1987-11-24
US5837541A (en) 1998-11-17
BE1000967A5 (fr) 1989-05-30
NO176924B (no) 1995-03-13
IL81370A0 (en) 1987-08-31
CN87102167A (zh) 1988-02-03
DE3703711A1 (de) 1987-09-24
NZ233920A (en) 1990-12-21
AT398781B (de) 1995-01-25
NL8700286A (nl) 1987-09-01
FR2595946B1 (fr) 1991-10-04
LU86761A1 (fr) 1987-09-15
GB2186592B (en) 1990-08-01
KR870007697A (ko) 1987-09-21
US5717071A (en) 1998-02-10
ATA26287A (de) 1994-06-15
PT84258B (pt) 1989-09-14
IE59627B1 (en) 1994-03-09
PT84258A (en) 1987-03-01
DK63187A (da) 1987-08-08
NO870476D0 (no) 1987-02-06
NZ219187A (en) 1990-12-21
SE8700467L (sv) 1987-08-08
GB8702689D0 (en) 1987-03-11
DE3703711C2 (Direct) 1993-06-24
HK21795A (en) 1995-02-24
CH672072A5 (Direct) 1989-10-31
FR2595946A1 (fr) 1987-09-25
HU203583B (en) 1991-08-28
IT1207589B (it) 1989-05-25
NO176924C (no) 1995-06-21
FI870502A0 (fi) 1987-02-06
GR870194B (en) 1987-06-10

Similar Documents

Publication Publication Date Title
FI94489C (fi) Menetelmä ristisuojaavien ihmisen monoklonaalisten vasta-aineiden valmistamiseksi ja vasta-ainetta tuottava solulinja
FI89278B (fi) Metod foer framstaellning av monoklonal human antikropp mot serotypiska lipopolysackariddeterminanter pao gramnegativa bakterier
Agüero et al. A plasmid-encoded outer membrane protein, TraT, enhances resistance of Escherichia coli to phagocytosis
JP2539797B2 (ja) グラム陰性菌の単クロ−ン抗体結合決定因子
Raff et al. Human monoclonal antibody with protective activity for Escherichia coli K1 and Neisseria meningitidis group B infections
KR910008361B1 (ko) 슈도모나스 이루지노사 항원형에 대한 교차면역 반응성 및 교차보호성 단일분지계 항체
HU201927B (en) Process for producing mycophenolic acid-(morpholinoethyl)-ester and its derivatives, as well as pharmaceutical compositions comprising such compounds
JPH02283294A (ja) ヒトモノクローナル抗体
Baumgartner Immunotherapy with antibodies to core lipopolysaccharide: a critical appraisal
JPS61500355A (ja) グラム陰性菌のエンドトキシンに対するモノクロナ−ル抗体
US4970070A (en) Protective monoclonal antibody compositions for infections due to group B streptococcus
McGhee et al. Induction of secretory antibodies in humans following ingestion of Streptococcus mutans
AU610819B2 (en) Cross-protective human monoclonal antibody compositions
Wagner et al. JM9 strains, a new type of group B streptococci from Japan
DE3745019C2 (de) Kreuz-schützende monoklonale Humanantikörper
Baumgartner Anti-endotoxin antibodies as treatment for sepsis-lessons to be learnt
McGhee et al. Research, University of Alabama in Birmingham, Birmingham, Alabama and Laboratory of Microbiology and
HARRIS RICHARD A. POLIN*,† AND MARY CATHERINE HARRIS

Legal Events

Date Code Title Description
FG Patent granted

Owner name: BRISTOL-MYERS SQUIBB COMPANY

BB Publication of examined application
GB Transfer or assigment of application

Owner name: BRISTOL-MYERS SQUIBB COMPANY

FD Application lapsed
MM Patent lapsed

Owner name: BRISTOL-MYERS SQUIBB COMPANY